Company Overview and News

 
New Century progresses zinc mine restart

2017-10-11 businessnews.com.au
Perth-based New Century Resources has locked in a $58 million debt facility agreement with investment firm Sprott, to fund the restart of operations at its Century zinc mine in Queensland.

 
Attila Resources Ltd to update on acquisition

2016-06-02 proactiveinvestors.com.au
Attila Resources Ltd (ASX:AYA) is preparing to update on the proposed acquisition of Veroguard Systems from Point of Pay Pty Ltd and SecurET Pty Ltd. The ASX has granted the company a trading halt, with its shares placed in pre-open. The halt will remain in place until the opening of trade on Monday 6th June 2016, or earlier if an announcement is made to the market.

 
Attila Resources Ltd edges closer to cyber security technology deal

2016-05-13 proactiveinvestors.com.au
Attila Resources Ltd (ASX:AYA) has completed due diligence on the acquisition of a privately owned cyber security infrastructure company which holds a binding agreement over another unlisted payment and cyber-security infrastructure company. SecurET is a party to a binding agreement with Australian-based payment and cyber-security infrastructure company, Point of Pay Pty Ltd to which SecurET has a right to acquire an interest in assets held by POP.

 
Quarterly Cashflow Report

2016-05-02 asx.com.au

 
Quarterly Activities Report

2016-05-02 asx.com.au

 
Primary Gold Ltd shares rally after $4 million share placement

2016-04-20 proactiveinvestors.com.au
Primary Gold Ltd (ASX:PGO) is a gold exploration and development company focussed on the Mt Bundy Gold Project near Pine Creek in Australia’s Northern Territory.

 
Half Yearly Accounts

2016-03-15 asx.com.au

 
Primary Gold Ltd makes new appointments, on comeback trail

2016-03-09 proactiveinvestors.com.au
Primary Gold Ltd (ASX:PGO) is a gold exploration and development company focussed on the Mt Bundy Gold Project near Pine Creek in Australia’s Northern Territory.

 
ALLOTMENT OF SHARES

2016-03-02 asx.com.au

 
Appendix 3B

2016-03-02 asx.com.au

 
Waiver of ASX Listing Rule 14.7

2016-02-18 asx.com.au

 
 
 
Attila Resources' shares in pre-open

2016-02-11 proactiveinvestors.com.au
Attila Resources (ASX:AYA) has been granted a trading halt by the ASX, with its shares placed in pre-open. Attila requested the halt pending the preparation of a response to a price query. The halt will remain in place until the opening of trade on Monday 15th February 2016, or earlier if an announcement is made to the market.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...